Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics

Journal of Pharmacological Sciences

Volumn 113, Issue 4, 2010, Pages 315-324

  Hughes, Jeff ^a   Crowe, Andrew ^a  

^a CURTIN UNIVERSITY   (Australia)

Author keywords

Azithromycin; Caco 2; Clarithromycin; Erythromycin; P glycoprotein

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; DIGITOXIN; DIGOXIGENIN; DIGOXIGENIN BISDIGITOXOSIDE; DIGOXIN; DIHYDRODIGOXIN; DRUG METABOLITE; ELACRIDAR; ERYTHROMYCIN; GLYCOPROTEIN P; MACROLIDE; PACLITAXEL; PROBENECID; ROXITHROMYCIN; VALSPODAR;

ARTICLE; CELL CULTURE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG EXCRETION; DRUG TRANSPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

EID: 77956197349     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.10109FP     Document Type: Article

References (40)

1. Mahdyoon H, Battilana G, Rosman H, Goldstein S, Gheorghiade M. The evolving pattern of digoxin intoxication: observations at a large urban hospital from 1980 to 1988. Am Heart J. 1990;120:1189-1194.
2. Einarson TR. Drug-related hospital admissions. Ann Pharmacother. 1993;27:832-840.
3. Abad-Santos F, Carcas AJ, Ibanez C, Frias J. Digoxin level and clinical manifestations as determinants in the diagnosis of digoxin toxicity. Ther Drug Monit. 2000;22:163-168.
4. Koren G, Woodland C, Ito S. Toxic digoxin-drug interactions: the major role of renal P-glycoprotein. Vet Human Tox. 1998;40:45-46.
5. Nordt SP, Williams SR, Manoguerra AS, Clark RF. Clarithromycin induced digoxin toxicity. J Accid Emerg Med. 1998;15:194-195.
6. Marik PE, Fromm L. A case series of hospitalized patients with elevated digoxin levels. Am J Med. 1998;105:110-115.
7. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289:871-878.
8. Lullmann H, Mohr K, Ziegler A, Bieger D. Color atlas of pharmacology. 2nd ed. Stuttgart: Thieme;2000.
9. Grahame-Smith D, Aronson J. Oxford textbook of clinical pharmacology and drug therapy. 2nd ed. Oxford: Oxford University Press;1992.
10. Laberge P, Martineau P. Clarithromycin-induced digoxin intoxication. Ann Pharmacother. 1997;31:999-1002.
11. Corallo CE, Rogers IR. Roxithromycin-induced digoxin toxicity. Med J Aust. 1996;165:433-434.
12. Marcus FI. Pharmacokinetic interactions between digoxin and other drugs. J Am Coll Cardiol. 1985;5:82A-90A.
13. Lindenbaum J, Rund DG, Butler VP Jr, Tse-Eng D, Saha JR. Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N Engl J Med. 1981;305:789-794.
14. Gooderham MJ, Bolli P, Fernandez PG. Concomitant digoxin toxicity and warfarin interaction in a patient receiving clarithromycin. Ann Pharmacother. 1999;33:796-799.
15. Wakasugi H, Yano I, Ito T, Hashida T, Futami T, Nohara R, et al. Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther. 1998;64:123-128.
16. Koren G, Klein J, Giesbrecht E, Ben Dayan R, Soldin S, Sellers E, et al. Effects of quinidine on the renal tubular and biliary transport of digoxin: in vivo and in vitro studies in the dog. J Pharmacol Exp Ther. 1988;247:1193-1198.
17. Hobley A, Lawrenson J. Ocular adverse effects to the therapeutic administration of digoxin. Ophthalmic Physiol Opt. 1991;11:391-393.
18. Wolin MJ. Digoxin visual toxicity with therapeutic blood levels of digoxin. Am J Ophthalmol. 1998;125:406-407.
19. Mitchell G. Adverse reactions to digoxin in four patients with normal or low serum digoxin levels. Med J Aust. 1997;167:111.
20. Gomes T, Mamdani MM, Juurlink DN. Macrolide-induced digoxin toxicity: a population-based study. Clin Pharmacol Ther. 2009;86:383-386.
21. Crowe A, Teoh YK. Limited P-glycoprotein mediated efflux for anti-epileptic drugs. J Drug Target. 2006;14:291-300.
22. Crowe A, Lemaire M. In vitro and in situ absorption of SDZRAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin. Pharm Res. 1998;15:1666-1672.
23. Artursson P. Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal asorbtive (Caco-2) cells. J Pharm Sci. 1990;79:476-482.
24. Youdim K, Qaiser M, Begley D, Rice-Evans C, Abbott N. Flavonoid permeability across an in situ model of the blood-brain barrier. Free Rad Biol Med. 2003;36:592-604.
25. de Bruin M, Miyake K, Litman T, Robey R, Bates S. Reversal of resistance by GF120918 in cell lines expressing the ABC halftransporter, MXR. Cancer Lett. 1999;146:117-126.
26. Aszalos A, Thompson K, Yin J, Ross D. Combinations of P-glycoprotein blockers, verapamil, PSC833, and cremophor act differently on the multidrug resistance associated protein (MRP) and on P-glycoprotein (Pgp). Anticancer Res. 1999;19:1053-1064.
27. Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Comm. 1991;175:880-885.
28. Schentag J, Bang A, Kozinski-Tober J. Digoxin. In: Burton M, Shaw L, Schentag J, Evans W, editors. Applied pharmacokinetics & pharmacodynamics: principles of therapeutic drug monitoring. 4th ed. Philadelphia: Lippincott Williams & Wilkins;2006.
29. Hinderling P, Hartmann D. Pharmacokinetics of digoxin and main metabolites/derivatives in healthy humans. Ther Drug Mon. 1991;13:381-401.
30. Belz G, Breithaupt-Grogler K, Osowski U. Treatment of congestive heart failure-current status of use of digitoxin. Eur J Clin Invest. 2001;31 Suppl 2:10-17.
31. Dobkin J, Saha J, Neu H, Lindenbaum J. Digoxin-Inactivating bacteria: identification in human gut flora. Science. 1983;220:325-327.
32. Citron D, Merriam C, Warren Y, Fernandez H, Goldstein E. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria. Antimicrob Agents Chemother. 2003;47:2334-2338.
33. Eberl S, Renner B, Neubert A, Reisig M, Bachmakov I, Konig J, et al. Role of p-glycoprotein inhibition for drug interactions: evi dence from in vitro and pharmacoepidemiological studies. Clin Pharmacokinet. 2007;46:1039-1049.
34. Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet. 1992;23:106-131.
35. Tsutsumi K, Kotegawa T, Kuranari M, Otani Y, Morimoto T, Matsuki S, et al. The effect of erythromycin and clarithromycin on the pharmacokinetics of intravenous digoxin in healthy volunteers. J Clin Pharmacol. 2002;42:1159-1164.
36. Hirata S, Izumi S, Furukubo T, Ota M, Fujita M, Yamakawa T, et al. Interactions between clarithromycin and digoxin in patients with end-stage renal disease. Int J Clin Pharmacol Ther. 2005;43:30-36.
37. Pachot J, Botham R, Haegele K, Hwang K. Experimental estimation of the role of P-glycoprotein in the pharmocaokinetic bahaviour of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco-2 cell model. J Pharm Pharm Sci. 2003;6:1-12.
38. Sugie M, Asakura E, Zhao Y, Torita S, Nadai M, Baba K, et al. Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin. Antimicrob Agents Chemother. 2004;48:809-814.
39. Takeuchi T, Yoshitomi S, Higuchi T, Ikemoto K, Niwa S, Ebihara T, et al. Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1. Pharm Res. 2006;23:1460-1472.
40. Gomes CM, van Paassen H, Romeo S, Welling MM, Feitsma RI, Abrunhosa AJ, et al. Multidrug resistance mediated by ABC transporters in osteosarcoma cell lines: mRNA analysis and functional radiotracer studies. Nuclear Med Biol. 2006;33:831-840.